TECHNICAL RATIONALE FOR TARGETING THE TUMOR’S FOLATE RECEPTOR

Folate receptor α (FOLR) is overexpressed in ~80% of ovarian cancers and is a validated therapeutic target. Indi Molecular’s initial clinical indication is Platinum-resistant, advanced stage patients – a population that badly needs new treatment options. 

We target the tumor’s overexpressed folate receptor with a PCC-based small molecule carrying 177Lu as the therapeutic killing agent. This overcomes the major challenges to a FOLR-targeted drug through:

• Ultra-high affinity (65 pM) for FOLR that displaces native folate binding to FOLR

• Elimination of renal uptake of therapeutic 177Lu, protecting the kidneys

Indi 177Lu-7327 has has been reviewed by FDA under a pre IND meeting format.

Indi-7327 is a theranostic molecule capable of functioning as a therapeutic agent or as a molecular imaging agent when utilizing Indi Imaging® technology.

Our CEO Presents:

Click through the slides below or watch our CEO, Albert A. Luderer, Ph.D., present them in the video above.